CNS Pharmaceuticals’ (NASDAQ:CNSP) European manufacturer, BSP Pharmaceuticals has begun the manufacturing process for Berubicin drug product.
The drug is a lead candidate for the treatment of glioblastoma multiforme or GBM, an aggressive form of brain cancer currently considered incurable.
The company’s focus remains on initiating a U.S. Phase 2 trial for Berubicin in Q1 of 2021.
“With the manufacturing of our Berubicin Drug Product in Europe, we continue to advance closer toward an IND filing for Berubicin, which we expect to submit later this quarter.” says John Climaco, CEO.